HIV Testing: A Complete Guide

This article is educational content based on current peer-reviewed guidelines, including WHO 2024, USPSTF 2019, CDC 2025, and the South African National Department of Health HIV testing algorithm as reproduced in the SAHCS 2025 PrEP Guideline. It is not personalised medical advice. Testing decisions and interpretation depend on the specific situation and must be made in consultation with a healthcare provider.

Who should be tested and how often

Current international guidance (USPSTF 2019, CDC, WHO) recommends routine HIV screening for all adolescents and adults aged 15 to 65, regardless of self-assessed risk. Under 15 and over 65, testing is recommended if risk factors are present.

The reasoning is simple. HIV is common enough, testing is accurate and affordable, and late diagnosis is dangerous. Risk-based testing both misses people who do not fit narrow criteria and reaches those who would benefit most, too late.

At minimum, everyone should test once. For most adults, that means sometime in young adulthood.

Annual testing is recommended for:

• Sexually active people, particularly with new or multiple partners
• Anyone with a recently diagnosed sexually transmitted infection
• People whose sexual partner(s) have HIV or are at risk for HIV
• Men who have sex with men (testing every 3-6 months if ongoing risk)
• People who inject drugs or share injection equipment
• People who exchange sex for money or other resources
• People considering or using PrEP (pre-exposure prophylaxis)

Test immediately if:

• You have had a possible exposure in the last 72 hours (this is the PEP window, see our PEP guide)
• You have symptoms of possible acute HIV infection (see below)
• You are starting a new sexual relationship and would like to know your status
• You are pregnant (testing is recommended at first antenatal visit and again in the third trimester)

Testing is not a judgment about your life. It's routine health maintenance, the same way you'd check blood pressure or cholesterol.

How HIV tests actually work: the three generations

HIV tests detect different markers depending on how recently the virus entered the body. Understanding the three generations helps interpret window periods correctly.

HIV RNA (nucleic acid amplification test, NAAT): Detects the virus itself, specifically, HIV genetic material in blood. This is the earliest marker to appear after infection, typically detectable from 6-8 days after exposure, sometimes up to 10-12 days. It's the most sensitive test for very early infection but also the most expensive, and it's not used for routine screening.

HIV p24 antigen (detected by 4th-generation tests): p24 is a protein on the outside of the virus particle. It becomes detectable from about 13-20 days after infection, roughly a week or two after HIV RNA. p24 levels then decline as antibodies start developing, which is why older antibody-only tests miss this early window.

HIV antibodies (detected by 3rd-generation and 4th-generation tests): These are the body's immune response to HIV. IgM antibodies become detectable around 20 days, IgG around 30 days after infection. Antibody levels then rise and remain detectable for life.

The practical takeaway:

• 4th-generation tests detect both p24 antigen AND antibodies, so they catch HIV earlier than antibody-only tests and are the current standard for laboratory screening.
• 3rd-generation tests detect antibodies only, slightly slower to turn positive in early infection but still accurate for established infection.
• NAAT/RNA tests are reserved for specific situations: suspected acute infection, resolving ambiguous results, or confirming diagnosis in infants.

Window periods: when it is too early to test

The "window period" is the time between HIV exposure and the test being able to detect infection. A test taken inside the window period can give a false negative, the person is infected, but the test doesn't yet show it.

Practical window periods for common tests:

• HIV RNA NAAT: positive from about 6-10 days after exposure
• 4th-generation lab test (Ag/Ab): positive from about 13-20 days after exposure in most people; by 4-6 weeks, close to 100% sensitive
• 3rd-generation rapid test (antibody only): positive from about 3-4 weeks after exposure in most people; by 12 weeks, reliably sensitive
• Self-test (antibody only): same as 3rd-generation rapid, reliably sensitive by 12 weeks

The 12-week rule:

A negative HIV test at 12 weeks (3 months) after the last possible exposure reliably rules out HIV. This is the standard used internationally. Earlier testing is useful for early detection, but a test at 6 weeks that is negative still needs a confirmatory test at 12 weeks if there was definitely an exposure.

If you have had a possible exposure within the last 72 hours, the most important thing is not to wait and test. Call the practice or go to an emergency unit today. PEP must be started within 72 hours and testing happens as part of that same consultation. See our PEP article for detail.

The South African testing algorithm (primary care)

South Africa's National Department of Health HIV testing algorithm, reproduced in the SAHCS 2025 PrEP Guideline, is a three-test rapid sequence specifically designed for point-of-care use in clinics and primary-care settings:

Step 1, Screening test: A rapid HIV test (finger-prick or oral fluid) is performed. If the result is non-reactive (negative), the result is reported as HIV-negative and no further testing is done.

Step 2, Confirmatory test 1: If the screening test is reactive (positive), a second rapid test using a *different* HIV assay is performed on the same sample. If this is also reactive, the algorithm proceeds to the third test.

Step 3, Confirmatory test 2: A third rapid test using yet another different HIV assay is performed. If this is also reactive, the result is reported as HIV-positive.

The three-test sequence uses three different assays to minimise false positives. This achieves a 99% positive predictive value, meaning that if all three tests are reactive, there is a 99% probability the person is truly HIV-positive.

Discrepant results: If the sequence gives conflicting results (for example, screening test reactive + confirmatory test 1 reactive + confirmatory test 2 non-reactive), the result is reported as HIV inconclusive, and the patient is referred for laboratory-based ELISA testing to resolve the ambiguity.

Why this algorithm: In the SA public sector, most HIV testing happens in primary-care clinics, often delivered by trained nurses or lay counsellors under the Nurse-Initiated and Managed Antiretroviral Therapy (NIMART) programme. Rapid tests give a same-day result, which means linkage to care can happen immediately, crucial for the "test and treat" strategy SA has adopted nationally.

The CDC laboratory algorithm (private labs and some settings)

In private laboratories, including those used by most SA medical aid schemes, HIV testing follows the CDC laboratory algorithm, which uses a different sequence:

Step 1, 4th-generation lab test (Ag/Ab combination immunoassay): Detects both p24 antigen and antibodies. If non-reactive, reported as HIV-negative.

Step 2, HIV-1/HIV-2 antibody differentiation assay: If the 4th-generation test is reactive, a confirmatory test distinguishes HIV-1 from HIV-2 antibodies. If positive for either, HIV is confirmed.

Step 3, HIV-1 RNA test (NAAT): If the 4th-generation test is reactive but the differentiation assay is negative or indeterminate, an RNA test resolves the discrepancy. A positive RNA confirms acute HIV infection; a negative RNA rules it out (the initial 4th-gen was a false positive).

Why this replaced the Western blot: The older algorithm used Western blot as the confirmatory test. The current CDC algorithm is faster, more sensitive for acute infection (because 4th-gen detects p24 antigen), can distinguish HIV-1 from HIV-2, and eliminates the ambiguous Western blot results that historically caused diagnostic delays.

Both algorithms are valid. The SA primary-care algorithm is optimised for rapid same-day results in clinic settings. The CDC lab algorithm is optimised for specificity in laboratory settings. In practice, SA patients may receive results from either, depending on where they test. At NeoHealth in George, both pathways are available, rapid testing in-rooms for a same-day result, or laboratory-based 4th-generation testing via local pathology where the clinical situation calls for it.

Rapid tests vs lab-based tests

Rapid tests (point-of-care):

• Results in 20-30 minutes
• Finger-prick blood or oral fluid sample
• Sensitivity and specificity typically >98% for established infection
• But: significantly less sensitive for acute (very recent) HIV infection, 3rd-generation rapid tests can miss up to 100% of very early infections; 4th-generation rapid tests detect about 67-82% of infections in the first 2-3 weeks
• All reactive rapid tests should be confirmed with laboratory-based testing

Laboratory-based 4th-generation tests:

• Results in 1-2 days (sometimes same-day in private labs)
• Venous blood sample
• Higher sensitivity for acute infection (due to better p24 antigen detection)
• Standard for initial diagnosis and confirmation

Which to choose in which situation:

• Routine screening in a well person: either is fine. Rapid tests give immediate results with counselling in the same visit.
• Recent exposure (last 6 weeks): laboratory-based 4th-generation preferred, because rapid tests may miss acute infection.
• After PEP: laboratory-based tests at 6 weeks and 12 weeks, following the SAHCS PEP guideline.
• Symptoms suggesting acute HIV infection: 4th-generation lab test plus HIV RNA (NAAT) to catch very recent infection.

HIV self-testing: accuracy and access

The World Health Organization approved HIV self-testing in 2016, and South Africa adopted these guidelines shortly after. Self-tests are antibody-based rapid tests, typically using oral fluid or finger-prick blood, read at home.

Accuracy:

Self-tests are highly accurate for established infection, sensitivity and specificity typically exceed 98%. They cannot reliably detect acute (recent) HIV infection, because they only look for antibodies, which take 3-4 weeks to develop.

Appropriate uses:

• Home-based testing for privacy or convenience
• Testing frequently between clinic visits for people at ongoing risk
• Secondary distribution to sexual partners
• Reaching people who don't access traditional healthcare
• Initiation and maintenance of oral PrEP or the vaginal ring (per SAHCS 2025 PrEP Guideline)

What self-tests cannot do:

• Replace laboratory confirmation after a reactive result
• Provide same-day counselling and linkage to care
• Detect very recent infection reliably
• Replace baseline testing before starting injectable PrEP (CAB-LA), which requires provider-performed testing

If a self-test is reactive:

Go to a healthcare provider within a few days for confirmatory testing using either the SA three-test rapid algorithm or a laboratory 4th-generation test. The SAHCS PrEP Guideline is explicit: *"In the event of a positive test result obtained through HIVST, this should be confirmed by a trained healthcare provider as soon as possible."*

In South Africa specifically:

The STAR Initiative distributed over 1 million self-test kits between 2017 and 2020 through pharmacies, community sites, workplaces, peer networks, and facility-based distribution. Self-tests are now available through some private pharmacies and public-sector programmes. Acceptability has been high, particularly for middle-aged and older adults in rural areas, and among groups historically under-tested.

Acute HIV infection: symptoms and why testing matters early

Acute HIV infection refers to the first few weeks after exposure, before antibodies have fully developed. Recognising it matters because viral loads are extremely high during this phase, often over 100,000 and sometimes over a million copies per mL, making transmission to partners dramatically more likely.

An estimated 40-90% of people with acute HIV develop symptoms, though these are often non-specific and mistaken for flu, glandular fever, or other viral illnesses. Symptoms usually appear 2-4 weeks after exposure.

Most common symptoms of acute retroviral syndrome:

• Fever (most common, reported by over 90% in some studies)
• Fatigue and generalised feeling of being unwell
• Sore throat (pharyngitis), often severe
• Headache
• Swollen lymph nodes (particularly neck, armpits, groin)
• Skin rash, typically a maculopapular rash involving the trunk
• Muscle and joint aches
• Mouth ulcers
• Diarrhoea

The symptoms are often described as "the worst flu I've ever had." They typically last 1-3 weeks and then resolve, after which the person often feels entirely well for years before HIV progresses without treatment.

Why testing during this window matters:

During acute infection:

• The risk of transmission to others is extremely high (viral load is at its peak)
• Treatment can be started early, which preserves immune function and improves long-term outcomes
• U=U messaging applies once treatment reaches viral suppression (see our long-term HIV management guide)

Testing for suspected acute HIV infection:

Standard antibody-only rapid tests may be negative during the first 2-4 weeks of infection. If acute HIV is suspected clinically (recent high-risk exposure plus compatible symptoms), testing should include:

• 4th-generation laboratory antigen/antibody test AND
• HIV RNA (NAAT / viral load test)

If both are negative and symptoms are compatible, repeat testing at 4-6 weeks and 12 weeks.

What different results mean

Negative result (HIV-negative):

• No evidence of HIV infection
• If exposure was more than 12 weeks ago, this reliably rules out HIV
• If exposure was in the last 6 weeks, a repeat test at 6 weeks and 12 weeks is recommended to account for window period
• Good opportunity to discuss ongoing prevention, PrEP for ongoing risk, condom use, regular testing

Positive result (HIV-positive):

Only reported after the full testing algorithm confirms it. In the SA primary-care algorithm, this means three reactive rapid tests; in the CDC lab algorithm, this means a reactive 4th-generation test plus a positive differentiation assay.

A confirmed positive result means:

• HIV infection is present
• Treatment is effective and available
• On modern therapy, life expectancy is near-normal
• Once virally suppressed, HIV cannot be transmitted to sexual partners (U=U)
• Immediate linkage to care is standard, ideally starting ART within 7 days, often same-day

Inconclusive or discrepant results:

Occasional. Can happen when tests disagree. The next step is laboratory-based ELISA testing, often followed by HIV RNA to resolve ambiguity. Most inconclusive results ultimately come back as either clearly negative (false reactive on the initial test) or reflect very early acute infection.

What happens after a positive diagnosis

A positive HIV test in 2026 is not what it was in 1996. HIV is now a treatable long-term condition with near-normal life expectancy on modern single-tablet therapy. Starting treatment is straightforward. The rest of this section covers what happens in the first two weeks after a confirmed diagnosis.

The immediate next steps:

1. Confirmation and counselling. The diagnosis is explained; time is given to process; questions are answered.
2. Baseline clinical and laboratory assessment. This typically includes:

• HIV viral load (to establish baseline)
• CD4 count (to assess immune status)
• HIV resistance genotype testing (where available, particularly in the private sector)
• Hepatitis B and hepatitis C screening
• Tuberculosis screening (symptom screen plus GeneXpert or chest X-ray if symptoms)
• STI panel (syphilis, gonorrhoea, chlamydia)
• Cryptococcal antigen screening if CD4 <100
• Full blood count and comprehensive metabolic panel
• Fasting lipid profile and glucose
• Pregnancy test (where applicable)

1. ART initiation. Same-day or within the first week is the current standard. For most adults, first-line therapy is a fixed-dose combination of tenofovir + lamivudine + dolutegravir (TLD), a single tablet once daily.
2. Structured follow-up. Typically at 2 weeks (tolerability check), 4 weeks, 3 months (viral load), then 6-monthly once stable.

Same-day ART initiation:

Multiple randomised trials have shown that starting ART on the day of diagnosis increases the likelihood of staying in care and achieving viral suppression. The RapIT trial in South Africa showed same-day initiation increased viral suppression at 10 months from 51% to 64%. The SLATE II trial, also in South Africa, showed same-day initiation increased the composite outcome of staying in care and being virally suppressed at 8 months from 59% to 74%.

Same-day ART is not appropriate in every situation, specifically, patients with suspected tuberculosis or certain opportunistic infections need those managed first. Dr Chellan's Diploma in HIV Management (CMSA) training includes this clinical judgment.

The likely timeline:

• Week 1: Diagnosis confirmed, baseline bloods drawn, ART started
• Week 4: First tolerability review, any side effects addressed
• Month 3: First viral load (should be undetectable or nearly so if adherence is good)
• Month 6: Second viral load; comorbidity screening review
• Month 12: Annual comprehensive review

See our detailed article on long-term HIV management for what care looks like across years.

Testing in pregnancy

All pregnant women in South Africa should be tested for HIV at the first antenatal visit, this is universal SA NDoH policy. A repeat test is recommended in the third trimester (ideally before 36 weeks), because new HIV infections during pregnancy are a major driver of mother-to-child transmission.

If positive in pregnancy:

• ART is started as soon as possible (usually the same day)
• The goal is full viral suppression by delivery, which dramatically reduces mother-to-child transmission
• With optimal management, the transmission rate is under 1%
• Dr Chellan and Dr Lakay co-manage HIV care in pregnancy, combining Dr Chellan's HIV qualification with Dr Lakay's antenatal care

See our full article on HIV in pregnancy for detail.

If repeatedly negative in pregnancy but ongoing risk:

PrEP is recommended and safe during pregnancy and breastfeeding. This is a major 2025 shift in SA guidance, the SAHCS 2025 PrEP Guideline explicitly recommends PrEP for pregnant and lactating people at ongoing risk.

Partner notification: your options

If you test HIV-positive, the question of telling sexual partners (or people with whom you have shared injection equipment) is ethically important and medically necessary, because testing them allows them to access treatment or PrEP.

Partner notification is voluntary in South Africa. No one can force you to disclose. But there are several supported options:

• Patient referral: You tell partners yourself, in your own time, your own way. Respects autonomy but has the lowest yield (many partners don't get tested).
• Contract referral: You agree to notify partners within a defined timeframe (typically 2-4 weeks). If they don't come in for testing, the provider contacts them.
• Provider referral: With your consent, a trained healthcare provider contacts the partner(s) and offers testing. The index patient is not named.
• Dual referral: The provider accompanies you to support disclosure.

Confidentiality: In all approaches, partners are notified that they may have been exposed to HIV, but they are not told who the index patient is. This is standard anonymous notification.

Evidence: Assisted partner notification approximately 1.5 times more effective at getting partners tested than patient self-referral alone, with very few reports of harm (such as violence or relationship breakdown) in studies.

The conversation about which approach suits your situation happens in the consultation with Dr Chellan, based on your specific circumstances and safety considerations.

HIV testing in South Africa: public vs private

Public sector:

• Free HIV testing at public clinics, hospital emergency units, antenatal clinics, STI services, and Thuthuzela Care Centres
• Available in approximately 96% of SA primary health facilities
• Delivered through the NIMART programme, nurses and trained lay counsellors provide testing with same-day rapid results
• Integrated with STI screening, contraception, TB screening, and chronic disease management
• Confidentiality protected by law

Private sector (including NeoHealth):

• Available through private GPs, hospitals, emergency departments, and some pharmacies
• Typically covered by medical aid schemes; specific coverage details vary
• Private pathology typically offers 4th-generation laboratory testing with same-day or 24-hour turnaround
• Same legal confidentiality protections
• Often more unhurried consultations with time for full pre- and post-test counselling

In George specifically:

• NeoHealth (Suite 12, Prince Vintcent Square, Gloucester Avenue, George Central). Dr Chellan offers confidential in-rooms HIV testing with rapid or laboratory options.
• Public clinics across the George metro offer free HIV testing integrated with other primary care services.
• Mediclinic George and George Hospital emergency departments can test when urgent.
• Thuthuzela Care Centre (serving the George area) offers testing as part of integrated post-assault care.

No aspect of an HIV test at NeoHealth involves your employer, your family members on dependent medical aid accounts, or anyone outside the clinical relationship. If you have specific confidentiality concerns, for example if you're on a partner's or parent's medical aid, we discuss these at the booking and adjust the approach.

For any questions about HIV testing, book a consultation with Dr Chellan at NeoHealth. Within our general practice, he offers full-spectrum HIV care, drawing on the Diploma in HIV Management (CMSA).

For Discovery Health members starting ART or already on treatment, NeoHealth can enrol you on the HIV Care Programme; both Dr Chellan and Dr Lakay are accredited Premier Plus HIV GPs.

For urgent PEP enquiries (a possible HIV exposure in the last 72 hours), call the practice immediately.

Important: This article provides general information on HIV testing based on current peer-reviewed guidelines, including USPSTF 2019, CDC 2021/2025, DHHS 2024, IAS-USA 2024, and the SA NDoH testing algorithm reproduced in the SAHCS 2025 PrEP Guideline. It is intended for educational purposes only. It is not personalised medical advice. Every situation is different. Please seek the advice of Dr Chellan or another qualified healthcare provider for any individual testing or medical concerns.

Sources and references

• Southern African HIV Clinicians Society. SAHCS HIV testing guidelines. Southern African HIV Clinicians Society.
• NDoH Knowledge Hub. South African HIV Testing Services Policy. South African National Department of Health.
• World Health Organization. Consolidated guidelines on HIV testing services. WHO.
• CDC. HIV testing laboratory algorithm. Centers for Disease Control and Prevention.
• HIV.gov. HIV testing and diagnosis clinical guidelines. US DHHS HIVinfo.
• SAHCS Self-Testing Position. HIV self-testing in South Africa. Southern African HIV Clinicians Society.
• Cohen MS et al.. Detection of acute HIV infection. NEJM 2011 (PubMed).

Content on this page is based on these sources and current clinical practice at NeoHealth. It is general health information, not personalised medical advice. Book a consultation for individual assessment.